Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Gene Therapy Ushering in a New Era in Disease Treatment - New analysis from Frost & Sullivan, U.S. Gene Therapies Market, reveals that revenues expect to reach approximately $125 million in 2006 and grow to a staggering $6541 million in 2011.
Gene Therapy Ushering in a New Era in Disease Treatment

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2005/12/02 - New analysis from Frost & Sullivan, U.S. Gene Therapies Market, reveals that revenues expect to reach approximately $125 million in 2006 and grow to a staggering $6541 million in 2011..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gene therapy is generating great excitement across the world due to its enormous potential in treating certain rare, inherited, or life-threatening diseases by inserting genes into the target cells of tissues or organs.

New analysis from Frost & Sullivan, U.S. Gene Therapies Market, reveals that revenues expect to reach approximately $125 million in 2006 and grow to a staggering $6541 million in 2011.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the U.S. Gene Therapies Market, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[...]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

“Gene therapy research has made exceptional progress and benefited from the growing body of information on the specific gene defects that cause inherited disorders,” says Frost & Sullivan Research Analyst Raghunath Tantry. “Research by the Human Genome Project, for instance, reveals the tremendous potential of treating patients based on their individual genetic make up.”

This project has identified various critical genes, such as an apoptosis gene - a gene that guides HIV viral reproduction and those of some colon and breast cancers.

Despite these remarkable strides, the fact remains that most biotech companies are still years away from having an approved and marketed product. The only exception to this is the China-based company Shenzhen SiBiono GeneTech Co. Ltd., whose product Gendicine, made news in October 2003 by becoming the first gene therapy in the world approved for marketing.

The approval signals a breakthrough in the treatment of head and neck squamous cell carcinoma (HNSCC), while ongoing clinical trials expect to uncover more target cancer indications for Gendicine. Following this development, there is a growing urgency among biotech companies to have a gene therapy approved in the United States.

“This is critical not only for treating the disease indication and offering hope to patients, but also to validate the whole gene therapy sector to the market and investors,” says Tantry. “Companies such as Introgen Therapeutics have potentially successful late-stage pipeline products and this will add to the market momentum and increase the credibility of the technology.”

Companies that do manage to secure approval will, however, have to contend with pressing concerns such as medico-ethical issues that are further likely to delay the road to market. Monitoring agencies are even questioning the ethics of testing these therapies on humans, since the science of genetics is still at a nascent stage of development.

Moreover, since the long-term impact of these therapies on humans remains unclear, their use is likely to be restricted to individuals resorting to novel treatments as a last course of action.

In the past, the image of gene therapy has been adversely affected by unfortunate setbacks. Now, as the industry attempts to overcome safety problems, participants must develop skillful communication strategies to increase awareness of gene therapy and position their own brands.

“Successes, even minor safety and efficacy milestones, must be communicated to overcome the unwanted publicity received for toxicity and fatalities,” says Tantry. “The market must be educated on the subtle ways to evaluate a gene therapy product for its benefits to patients that need those therapies.”

U.S. Gene Therapies Market, part of the Pharmaceutical subscription, examines the present performance of pipeline gene therapy products at discovery and clinical development levels and evaluates their future market potential. It tracks and discusses the most critical technological breakthroughs in gene therapy research. The study also examines vectors and delivery systems in the pipeline and analyzes them by type and application. Analyst interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

U.S. Gene Therapies Market
F414

Contact:

Radhika Menon Theodore
Corporate Communications – Europe
P: +91 (044) 52044668
E: rmtheodore[.]frost.com

Donna Jeremiah
Corporate Communications – Asia Pacific
P: +603 6304 5832
F: +603 6201 7402
E: djeremiah[.]frost.com

Surbhi Dedhia
Corporate Communications – India
P: +91 22 2832 4705 Ext: 131
E: sdedhia[.]frost.com

Keywords in this release: Gene therapy, Human Genome Project, Gendicine, Shenzhen SiBiono GeneTech, head and neck squamous cell carcinoma, HNSCC, Introgen Therapeutics, research, information, market, trends, technology, service, forecast, market share

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Gene Therapy Ushering in a New Era in Disease Treatment

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Thales Launches the Pixium Portable 3543 DR Wifi Enabled Flat Panel Detector
GE Healthcare Showcases Industry-first Technologies and Digital Solutions, Focused on Improving Outcomes, At RSNA 2016
Agfa and LCsys Team Up to Launch ABSOLUT-ID, Their Turnkey Integrated Solution for the Production of High Security ID Cards
ZOLL Technology for Improving CPR Quality to be Showcased at American Heart Association Annual Conference
AccuVein to Exhibit Leading Vein Visualization Technology at American Society for Dermatologic Surgery Annual Meeting
US Biomedical Textiles Transform Implant Device Technology by Aligning to Changes in Patient Preference Finds Frost & Sullivan
Frost & Sullivan Commends Influence Health for Constantly Evolving its Patient Engagement Products to Accelerate Market Transformation
Frost & Sullivan Awards Carestream Top Honors for OnSight 3D Extremity System
Sparta Systems Launches the Next-Generation Cloud Solution Stratas QMS
Koning Wins Accolades from Frost & Sullivan for the Impressive Innovation Behind its Groundbreaking KBCT Breast Imaging Device

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today